

Special Issue

Diagnosis for SARS-CoV-2 Infections

Message from the Guest Editors

Dear colleagues, This Special Issue of MDPI's *Vaccines* focuses on the recent advances and future prospects in the field of SARS-CoV-2 diagnosis. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Rapid, sensitive, specific, and scalable diagnosis and monitoring of SARS-CoV-2 infections.
- Limitations of current diagnostic testing and recent developments in the field of SARS-CoV-2 diagnosis to identify specific variants of concern.
- Serodiagnostic tests and their effectiveness for diagnosing SARS-CoV-2 infection
- The role of antibodies in SARS-CoV-2 diagnosis
- Plasma levels of pro-inflammatory and anti-inflammatory cytokines associated with the progression and severity of SARS-CoV-2 infection.
- Underlying host immune responses against SARS-CoV-2 infection.
- Specific immunological responses and inflammatory markers distinguishing SARS-CoV-2 infection from clinically similar non-COVID-19 viral infections.

We look forward to receiving your contributions.

Guest Editors

Dr. Rajiv Pathak

Department of Genetics, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann Building, Room 823 Bronx, New York, NY 10461, USA

Dr. Prajna Tripathi

Microbiology and Immunology, Weill Cornell Medical College, New York, NY 14853, USA

Deadline for manuscript submissions

closed (29 February 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/159092

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).